Endocrine Month in Review: July 2021

July 31, 2021

July's month in review features stories related to new diabetes medications, National Kidney Foundation guidance, and FDA news. Check back in during the last weekend of each month for the next Endocrine Month in Review.

Endocrinology Network's Meet the Board: Elaine Apperson, MD

July 12, 2021

To allow our audience to become more acquainted with our advisory board members, Endocrinology Network will be hosting a special content series highlighting our board members, their practices, and why they were invited to help guide coverage moving forward.

Early Life BMI Plays Role in Future Diabetes and CVD Risk, Regardless of Adult BMI

June 22, 2021

Using 24 years of follow-up data from more than 12k adolescents provides insight into the impact of childhood BMI z-scores on risk of adverse health outcomes, including development of diabetes and premature myocardial infarction, in adulthood.

Heart Failure Risk Among Children Born Preterm Persists Through Adulthood

April 06, 2021

An analysis of more than 4 million singleton births indicates children born at an early gestational age were at an increased risk of heart failure at multiple points throughout life when compared to their counterparts not considered preterm births.

Dasiglucagon (Zegalogue) Approved by FDA for Severe Hypoglycemia in Children and Adults

March 22, 2021

Zealand Pharma announced the US FDA approved dasiglucagon (Zegalogue) for treatment of severe hypoglycemia in patients with diabetes aged 6 and older and the injectable will be available as both an auto injector and a prefilled syringe.